Digene SurePath “Not-Approvable” Letter Expected After FDA Data Request
This article was originally published in The Gray Sheet
Executive Summary
Digene will be required to submit additional clinical data to FDA to support its application for use of TriPath's SurePath test pack as a specimen collection medium for the Hybrid Capture 2 (HC2) human papillomavirus (HPV) test
You may also be interested in...
Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
TriPath accuses Cytyc of unlawful business interference in an unfair competition/patent infringement lawsuit filed June 17
Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
TriPath accuses Cytyc of unlawful business interference in an unfair competition/patent infringement lawsuit filed June 17
HPV DNA Pap Test Approved As Primary Screen; New Guidelines Expected
Digene is evaluating various methods of marketing its human papillomavirus (HPV) test to ob/gyn physicians following expanded approval for primary cervical cancer screening March 31